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esponsibility of InstAbstract A phospholipid-based injectable gel was developed for the sustained delivery of leuprolide
acetate (LA). The gel system was prepared using biocompatible materials (SPME), including soya
phosphatidyl choline (SPC), medium chain triglyceride (MCT) and ethanol. The system displayed a sol
state with low viscosity in vitro and underwent in situ gelation in vivo after subcutaneous injection. An
in vitro release study was performed using a dialysis setup with different release media containing
different percentages of ethanol. The stability of LA in the SPME system was investigated under different
temperatures and in the presence of various antioxidants. In vivo studies in male rats were performed to
elucidate the pharmacokinetic proﬁles and pharmacodynamic efﬁcacy. A sustained release of LA for 28
days was observed without obvious initial burst in vivo. The pharmacodynamic study showed that once-a-
month injection of LA-loaded SPME (SPME-LA) led to comparable suppression effects on the serum
testosterone level as observed in LA solution except for the onset time. These ﬁndings demonstrate
excellent potential for this novel SPME system as a sustained release delivery system for LA.
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Prostate cancer is the most commonly diagnosed cancer and
accounts for high mortality among men. Routine treatments for
prostate cancer include surgical intervention, radiotherapy and
chemotherapy. Since prostate cancer cells depend on androgens for
proliferation and growth, androgen deprivation remains the most
prevalent treatment for prostate cancer. This is especially the case
for advanced prostate cancer1. Clinically, androgen deprivation
therapy includes medical and surgical castration. Notably, the
effects of medical castration are comparable to surgical castration
with bilateral orchiectomy2.
Regarding medical castration, luteinizing hormone release
hormone (LHRH) agonist analogs are often used for the effective
downregulation of LHRH receptors3, thereby indirectly decreasing
testosterone levels. Among various analogs, leuprolide acetate
(LA), a potent LHRH agonist, is often used clinically for medical
castration. As a water-soluble peptide, LA requires repeated
injections to obtain desirable therapeutic effect due to extremely
short half-lives in vivo4. The poor patient compliance resulting
from repetitive injections greatly limits this medical use for LA. To
solve this problem, various long-term sustained-release prepara-
tions, such as microspheres5–7, implants8 and in situ forming
implants9–11 have been prepared and studied. Among these, in situ
forming implants based on phase separation show several advan-
tages including ease of preparation and lack of required surgery.
After being subcutaneously administered in liquid form, in situ
forming implants gradually form a solid or semisolid drug delivery
depot at the injection site by solvent exchange. Eligard12, a
commercial in situ forming implant of LA, shows sustained drug
release over one-, three-, four- and six-month periods. Never-
theless, in situ forming implants are also associated with potential
safety concerns for the presence of high organic solvents in the
polymer matrix, such as N-methyl-2-pyrrolidone (NMP, about
55%, w/w)13. Moreover, the high initial burst due to fast phase-
transition of the implants in vivo remains unresolved14.
Our group recently developed a novel injectable in situ forming
gel delivery system. The gel system, herein named SPME, was
prepared by mixing soya phosphatidyl choline (SPC), medium
chain triglyceride (MCT) and ethanol. SPME has several advan-
tages over poly(lactide-co-glycolide) (PLGA)-based in situ form-
ing implants, namely minimal amounts of organic solvent,
excellent biocompatibility, and signiﬁcantly less burst effects.
Unlike most polymeric in situ forming implants, the novel SPME
system is based on the phase separation of phospholipids in vivo.
As the main component of cell membrane, phospholipids are
biologically compatible, and soluble in ethanol, yet display poor
solubility in water. When administrated in the liquid form, the
SPME system undergoes phase separation, thus resulting in the
formation of a solid or semisolid gel at the injection site due to the
in situ water–ethanol exchange between the surrounding body
tissues and the SPME system. Phospholipid-based in situ forming
gel drug delivery systems have been successfully applied to the
long term delivery of various drugs, such as doxorubicin15,
bromotetrandrine16 and exenatide17. Previous studies reported that
when loaded with octreotide, the gel system showed extended
release for 30 days in vivo18.
The present study aimed to investigate the application of the
SPME system as a long term drug delivery platform for LA. The in
vitro and in vivo release proﬁles of LA from the SPME system
were investigated systematically. Next, the stability of LA in the
SPME system was investigated under different temperatures and inthe presence of various antioxidants. Finally, in vivo studies in
male rats were performed to elucidate the pharmacokinetic proﬁles
and pharmacodynamic efﬁcacy of this preparation.2. Materials and methods
2.1. Materials
Soya phosphatidyl choline (SPC, Lipoid S100) was obtained from
Lipoid (Germany, 579010-1140034-04/902). Medium chain tri-
glyceride (MCT) was obtained from Beiya Medical Oil Co., Ltd.
(Tieling, China, y110501-3-01). Ethanol was provided by Tianhua
(Chengdu, China). Leuprolide acetate (LA) was supplied by Kaijie
(Chengdu, China). (7)-α-Tocopherol was obtained from Sigma–
Aldrich (St Louis, MO, USA). Glycine was provided by Kemiou
(Tianjin, China). All the other chemicals and reagents were of
analytical grade.
2.2. Animals
Male Sprague–Dawley (SD) rats (8 weeks old, 300720 g) were
obtained from Experimental Animal Center of Sichuan University
(Chengdu, China). During the study, the rats were given free
access to food and water ad libitum. All animal experiments were
performed according to China's Animal Welfare Legislation and
the Institutional Animal Care and Use Guidelines of Sichuan
University.
2.3. Preparation of SPME-LA and evaluation of viscosity
LA-loaded SPME (SPME-LA) was prepared by mixing SPC,
MCT, and 90% (v/v) ethanol (70:15:15, w/w/w) and stirred for 1 h.
For viscosity measurement, dialysis method was applied to
simulate the phase separation process. A volume of 20 mL
SPME-LA was put into a dialysis bag and then incubated in 4 L
of 0.1 mol/L PBS (pH 7.4) under shaking. The Brookﬁeld DV-C
rotational viscometer was used to measure the viscosities of
SPME-LA before (sol) and after phase separation (gel).
2.4. In vitro release experiment
LA solution (300 μL, 3.75 mg/mL) or SPME-LA (300 μL, equiva-
lent to 3.75 mg/mL LA) was added into dialysis bags and the
dialysis bags were placed in 4 mL of different release media
containing 0.1 mol/L PBS (pH 7.4) with varying percentages of
ethanol (0, 10%, 20% or 30%, v/v). The release setup was
maintained under shaking at 37 1C. At given time intervals, the
entire media was removed and replaced with prewarmed fresh
media. The concentration of LA in the release media was analyzed
by high performance liquid chromatography (HPLC, Agilent
Technologies 1200 series) using UV detection at 220 nm, a
Kromasil C18 column (150 mm 4.6 mm, 5 mm) at 30 1C. The
mobile phase consisted of 0.1% trifuroacetic acid and acetonitrile
(68:32, v/v), and ﬂowed through the column at the rate of 1.0 mL/
min. The cumulative released amount of LA was calculated
according to the following equation (1) 19:
Cumulative amount released %ð Þ ¼
Xt
t ¼ 0
Mt
Mtheoretical
 
 100
ð1Þ
Figure 1 Schematic representation of subcutaneous administration of
the in situ forming gel ((1) epidemis and dermis; (2) subcutis; and
(3) muscles). SPME-LA displays a yellow and transparent appearance
in vitro (A), and it forms a creamy-yellow gel after subcutaneous
administration in vivo (B). Scale bar: 1 cm.
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Mtheoretical represents the theoretical amount of LA in the
formulation.
2.5. Stability study
Different formulations with or without antioxidants were prepared
and divided into three groups: group 1, a control group without
antioxidants; group 2, containing 0.0001% glycine; group 3,
containing 0.2% (7)-α-tocopherol. Afterwards, each ampule was
ﬁlled with 0.3 mL of formulation and then sealed. The ampules
were stored in dark at 4 1C and 37 1C. At predetermined time
points, ampules were taken out and restored to room temperature.
The drug was extracted from the SPME-LA according to the
following procedures: 20 mg of formulation was weighed accu-
rately followed by vortexing with 2.55 mL of 0.1 mol/L PBS (pH
7.4) for 5 min, 450 μL of 5% tritonX-100 solution as demulsiﬁer
was then added and centrifuged at 10,000 rpm (3K15 high-speed
refrigerated centrifuge, Sigma, German) for 5 min after a brief
vortexing. The supernatant was passed through a 0.22 μm mem-
brane ﬁlter and 20 μL was injected into the HPLC system for
analysis. The remaining percentage amounts of LA at different
times were calculated and normalized to value of day 0.
2.6. In vivo studies
The in vivo studies were evaluated in SD rats (male, 300720 g). For
the pharmacokinetic study, 1 mL of LA solution (3.75 mg/mL) or
SPME-LA (equivalent to 3.75 mg/mL LA) was subcutaneously
injected into the back of the rats (six animals per group) at a dose
of 12.5 mg/kg. Blood samples were collected into the tubes with Na-
heparin at 0.25, 0.5, 1, 2, 4, 6, 8, 12 h, 1, 3, 5, 7, 10, 13, 16, 20, 24,
and 28 days after administration of SPME-LA, while blood samples
were collected at 0.25, 0.5, 1, 2, 4, 6, 8, 12 h, 1, 2, and 3 days after
administration of free LA. Plasma was obtained following centrifuga-
tion at 4500 rpm for 10 min and stored at –80 1C until further analysis.
The LA concentration was measured by a modiﬁcation of the
published method20. Acetonitrile (200 μL) was added to 100 μL of
plasma, the mixture was vigorously vortexed for 5 min and centrifu-
gated at 15,300 rpm for 5 min. The supernatant was passed through a
0.22 μm membrane ﬁlter and 1 μL of ﬁltrate was analyzed by liquid
chromatography tandem mass spectrometry (LC–MS/MS). The LC–
MS/MS analysis was performed with an Agilent 1200 series system
(Agilent Technologies Co., Ltd., USA) equipped with a SL binary
pump, SL autosampler, vacuum degasser, and an Agilent triple-
quadruple MS. The mobile phase consisted of 0.1% formic acid and
acetonitrile (75:25, v/v), and ﬂowed through a Diamonsil ODS column
(50 mm 4.6 mm, 1.8 μm) at the rate of 0.4 mL/min. The mass
spectrometric analysis was performed under electrospray ionization
(ESI). For the quantiﬁcation of LA, the transition of m/z 605.5-221.1
was adopted under multiple-reaction monitoring (MRM) positive
mode. The voltage of fragmentor potential and collision energy were
set as 132 and 36 eV, respectively. The ﬂow rate and temperature of
nebulizer gas (N2) were set as 10 mL/min and 350 1C, respectively.
The nebulizer is 30 psi, and the capillary is 4000 V.
For pharmacodynamic study, 25 rats were randomly divided into
ﬁve groups (A, B, C, D, and E) with ﬁve animals in each group. Group
A, untreated control, received no injection to observe the normal
ﬂuctuation of serum testosterone levels. Group B received 1 mL
subcutaneous injection of LA saline solution once a day for 35
consecutive days at a dose of 100 μg/kg. The other three groups (C, D,and E) received 1 mL subcutaneous injection of SPME-LA at doses of
0.9, 2.25, and 3.75 mg/rat, corresponding to doses of 3, 7.5, and
12.5 mg/kg, respectively. Blood samples were collected into the tubes
at 0, 3, 6 h, and 1, 2, 3, 7, 14, 21, 28 and 35 days after administration,
and were centrifuged at 4 1C and 3000 rpm for 10 min to obtain serum
which was immediately stored at –80 1C until further analysis of
testosterone levels by Testosterone ELISA Kit (Cloud-Clone Corp.,
China).
2.7. Statistical analysis
All data were expressed as mean7standard deviation (SD). Statistical
comparisons between two groups were performed using student's t-test.
Results in the pharmacokinetic study were analyzed using DAS
3.0 software (Drug and Statistics, Shanghai, China). Results in the
pharmacodynamic study were evaluated by one-way ANOVA fol-
lowed by a Tukey post hoc test using GraphPadPrism version 5.0
(GraphPad Software). P values of 0.05 or less were considered
statistically signiﬁcant.3. Results and discussion
3.1. SPME-LA preparation and viscosity measurement
As shown in Fig. 1A, SPME-LA displayed a yellow, transparent
appearance before injection. In this formulation, SPC was used as
the core component and 90% (v/v) ethanol was used to dissolve the
drug LA and SPC, while MCT was used as a combined solvent to
reduce the amount of ethanol which might cause skin irritation. In
addition, SPC and MCT showed good biocompatibility, and the
ethanol concentration was less than 15% (w/w), which would not
cause severe side effects.
The SPME remained as a solution in vitro before injection and
rapidly underwent phase separation to form semisolid gels after
injection (Fig. 1B). During the phase separation process, a signi-
Danhong Long et al.332ﬁcant change of viscosity was accompanied by this sol-gel
separation. As shown in Fig. 2, the initial viscosity of SPME-
LA was 251.2 cP, which is below the threshold viscosity of 300 cP
for injection21, indicating a viscosity which was suitable for
injection. After separation, the viscosity was approximately
4567 cP, indicating the formation of a semisolid gel.3.2. In vitro release studies
As shown in Fig. 3, the release of LA from SPME-LA groups
showed a sustained release pattern for up to 30 days, whereas free
LA showed a 80% cumulative drug release after 8 h. Moreover,
the release rate of LA from SPME-LA increased as the content of
ethanol increased. About 30% LA was released from SPME-LA in
PBS-only media for 28 days. Conversely, approximately 60% LA
was released from SPME-LA in the PBS containing 10% (v/v)
ethanol, and more than 90% LA was released in the PBS with 20%
and 30% of ethanol (v/v), which might be attributed to the
solubility of SPC in ethanol. Accordingly, SPC dissolved faster
in the release media with higher percentages of ethanol, thereby
resulting in faster drug release.Figure 3 In vitro release of LA from SPME-LA or LA solution in PBS (p
are presented as mean7SD, n¼3.
Figure 2 Viscosity of SPME-LA in sol and gel state at 25 1C. Data
are presented as mean7SD, n¼3.To elucidate the release mechanism, various mathematical
models were used including zero-order, ﬁrst-order kinetics, Higu-
chi, Weibull and Ritger–Peppas models. Correlation coefﬁcient R2
was chosen to evaluate the ﬁtting degree of an individual model.
The Ritger–Peppas model showed the best correlation to experi-
mental data. For the Ritger–Peppas model, the release process is
driven by Fickian diffusion (no0.45), non-Fickian diffusion
(0.45ono0.89), and matrix erosion (n40.89)22. In our study,
the value of n ranged from 0.3999 to 0.4540, indicating that the
release of LA process was mainly driven by Fickian diffusion and
gradually accompanied by dissolving the gel with higher content
of ethanol. Thus, the release of drug increased as the content of
ethanol increased. More importantly, no apparent initial burst was
observed in any of the release media. A single peak of LA in the
HPLC chromatograms was observed indicating that LA remained
stable in the release media.3.3. Stability study
Fig. 4 showed the results of storage stability study of LA in the
SPME. Antioxidants greatly impacted the stability of LA in the
formulation, while temperature showed minimum inﬂuence on the
stability of LA. Group 1, without antioxidants, was unstable for
long-term storage because the remaining percentage of LA after 28
days was about 80% at 4 1C and 37 1C. In contrast, LA in the
groups containing antioxidants showed acceptable stability whose
content decreased by 10% after 28 days in the presence of
0.0001% glycine or 0.2% tocopherol except for the group 3 at
37 1C whose content decreased by 17%.
SPME was a phospholipid-based phase separation gel in which
SPC was used as the core component. A general question
encountered in phospholipid-based formulation is the stability of
phospholipids, which can easily undergo oxidation under normal
storage conditions. Liposomes, mainly composed of phospholipids
and cholesterol, are extensively used as a carrier system for
chemotherapeutics. However, liposomes often suffer from chemi-
cal instability due to phospholipid oxidation23. In this study,
different kinds of antioxidants were added in the SPME formula-
tion, and a systematic study was conducted to investigate whether
the oxidation of SPC would affect the stability of LA. Glycine was
used as a water-soluble antioxidant, and (7)-α-tocopherol wasH 7.4) containing 0, 10%, 20% and 30% (v/v) of ethanol at 37 1C. Data
Figure 5 Plasma concentration of LA after a single subcutaneous
injection of free LA and SPME-LA at a dose of 12.5 mg/kg in rats.
Data are presented as mean7SD, n¼6.
Table 1 Pharmacokinetic parameters of leuprolide acetate
(LA) after subcutaneous injections of free LA and SPME-LA
in rats.
Parameter Dose (12.5 mg/kg)a
Free LA SPME-LA
Cmax (ng/mL) 2783.8771283.04 227.64766.68
**
Tmax (h) 0.5070.27 1.2570.61
*
AUC0–t (ng  h/mL) 9729.4872695.70 12733.0371467.57*
AUC0–1
(ng  h/mL)
9838.2472651.47 13564.3171806.84*
t1/2 (h) 18.3579.02 139.02797.57
*
aData are presented as mean7SD, n¼6.
*Po0.05.
**Po0.01 vs. free LA.
Figure 4 Storage stability of LA in SPME with or without
antioxidants at 4 1C (A) and 37 1C (B). SPME-LA without antiox-
idants was served as control. *Po0.05, **Po0.01 vs. control group at
the same time. Po0.05 vs. 0.2% tocopherol group at the same time.
Data are presented as mean7SD, n¼3.
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signiﬁcant differences between control group and the other two
groups from day 14 to day 28 both at 4 1C and 37 1C (P o 0.05).
More obviously, the presence of glycine showed better antioxidant
effect than (7)-α-tocopherol at 37 1C, implying that SPC oxida-
tion might affect the stability of LA in the SPME-LA. Hence,
antioxidants are necessary to maintain the stability of the gel
formulation, and ﬁlling with nitrogen was also critical to long-term
storage. Further study is required to investigate other approaches
for maintaining stability during long-term storage.3.4. In vivo studies
Plasma levels of LA in rats after subcutaneous injection of LA
solution and SPME-LA are shown in Fig. 5. After subcutaneous
administration of LA solution, LA concentrations increased
quickly and reached a maximum value of 2783.91 ng/mL within
1 h, followed by a rapid clearance. In contrast, the maximum
concentration of LA was 227.64 ng/mL after injection of SPME-
LA, which then gradually decreased but maintained above the
minimal therapeutic concentration for up to 28 days. The t1/2
values of the SPME-LA and LA solution were 139.02797.57 and
18.3579.01 h, respectively. A paired t-test showed that pharma-
cokinetic parameters between free LA and SPME-LA had sig-
niﬁcant differences (Table 1).SPME-LA showed a signiﬁcantly lower Cmax value than that
found for the LA solution, indicating that the initial burst of
SPME-LA was much lower than that of LA solution. According to
literature, the initial burst of PLGA/NMP system is caused by the
fast phase-transition14. However, for the SPME system, the initial
burst may be attributable to the diffusion of ethanol during phase
separation. The percentage of ethanol in the pregel solution was
limited, thereby causing a less signiﬁcant initial burst. On the other
hand, the t1/2 value of the SPME was much longer than that of the
LA solution, indicating a sustained release of LA from SPME-LA.
For pharmacodynamic studies, testosterone levels have been
regarded as an important pharmacological index for LHRH agonist
therapy to monitor castration levels. In this study, testosterone
levels were monitored for 35 days, and the serum testosterone
level of each group was compared with the chemical castration
threshold (0.5 ng/mL). Fig. 6 presents the ﬂuctuations of the mean
level of serum testosterone in rats of ﬁve groups. Group A, an
untreated control, showed the natural ﬂuctuation of serum testos-
terone levels which were greater than castration levels within 35
days. In contrast, the mean levels of serum testosterone of all LA-
treated groups demonstrated a transient surge immediately after the
initial administration of LA, and were reduced slowly or rapidly
during the treatment of LA. This is likely to be related to the
Figure 6 Serum testosterone levels in rats after subcutaneous
administration of LA for 35 days. Untreated control (■); Free LA, a
consecutive injection at a dose of 100 μg /kg/d for 35 days (●); SPME-
LA, a single injection at a dose of 3 mg/kg (▲), 7.5 mg/kg (▼),
12.5 mg/kg (◆). The dash dotted line represents the chemical castration
threshold (0.5 ng/mL). **Po0.01 vs. untreated control. Data are
presented as mean7SD, n¼5.
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sections to produce luteinizing hormone to directly act on testis to
produce testosterone. However, LHRH receptors are down-
regulated because of the sustained release of LA, and as a result,
the production of luteinizing hormone is reduced which then
decrease the production of testosterone. For group B, the mean
level of serum testosterone in rats increased from 0.14 to
0.54 ng/mL three hours after the initial subcutaneous injection of
LA solution. Afterwards, the mean level of serum testosterone
decreased rapidly to the castration level on day 2, and maintained
the inhibitory effect until day 35. This result further implied that a
sustained release of LA was required to achieve and keep the
castration level of testosterone.
The other three groups received different doses of SPME-LA
for an effective dose study. Rats in group C which received a
single injection of SPME-LA at a dose of 3 mg/kg were
insufﬁcient to suppress the serum testosterone level to the
castration level. Conversely, the serum testosterone level in rats
receiving a dose greater than 3 mg/kg showed a different pattern
over treatment. The mean serum testosterone concentration of rats
in groups D and E increased from 0.29 and 0.12 ng/mL to 0.64
and 0.50 ng/mL three hours after the subcutaneous injection of
SPME-LA at doses of 7.5 and 12.5 mg/kg, respectively. After-
wards, the serum testosterone level of rats in groups D and E
decreased slowly to the castration level on day 7, and maintained
the therapeutic level until day 35. There were no signiﬁcant
differences between LA solution and SPME-LA groups (B and D,
B and E, P40.05) during the therapeutic period from day 7 to day
35. Moreover, groups D and E showed a similar testosterone
suppression effect without any signiﬁcant difference (P40.05).
No apparent weight loss or skin irritation was observed in any of
the treated rats during the whole study. Therefore, the minimal
effective dose using SPME-LA is probably greater than 3 mg/kg
and less than 7.5 mg/kg.
Consistent with the in vitro release study, LA solution exhibited
the fastest release and resulted in the shortest onset time after daily
subcutaneous administration. In contrast, SPME-LA achievedsustained drug release for 28 consecutive days in vitro and
resulted in a persistent suppressive effect of testosterone release
in vivo except for the group C which received an injection of
SPME-LA at a dose of 3 mg/kg. In this study, the dose of 3 mg/kg
was designed to correspond to the dose of 100 μg/kg/d at steady
state for 30 days. However, 3 mg/kg was proven unable to
suppress the serum testosterone level to castration levels, possibly
attributable to the dose loss. For example, the dose loss for the
once-a-month injectable microspheres of LA was nearly 25%
which was mostly caused by the initial burst and the residual at the
injection site25. As for the SPME-LA system, one of the reasons
causing dose loss is possibly owing to the amount of gel remaining
at the injection site. As discussed for in vitro release study, only
30% LA released from SPME-LA in the PBS-only media for 28
days indicating that the majority of LA remained in the dialysis
bag. Moreover, the rats were sacriﬁced and dissected at day 35,
and SPME-LA remaining at the injection site was observed.
Therefore, the amount of LA remaining at the injection site might
explain the dose loss. As discussed above, since phospholipids are
the core component of the SPME-LA, phospholipid degradation
determines the release rate of drug. For example, in
macromolecule-loaded vesicular phospholipid gels (VPGs), the
drug release is governed by the erosion of phospholipids matrix,
and as a result, higher lipid concentrations retard the erosion
process26. In this paper, the high phospholipids concentration
(70%) with low viscosity was chosen in order to achieve a longer
sustained release of drug, substantiated by the pharmacokinetic
and pharmacodynamic studies. Based on the literature, the volume
of pitavastatin-loaded phospholipid gel decreased gradually over
time, indicating the phospholipid-based gel is biodegradable27.
Therefore, advantages such as the ease of preparation, biodegrad-
ability and sustained release properties demonstrate the potential of
the SPME system as a new and effective sustained delivery system
for LA.4. Conclusions
A phospholipid-based injectable gel was developed for the long-
term delivery of LA in this study. Both in vitro and in vivo studies
showed a sustained release of LA from SPME system for 30
consecutive days. A preformulation and stability study showed
that the presence of antioxidants enhanced the stability of LA
during storage. Moreover, serum testosterone levels in male rats
decreased to castration levels on day 7, and maintained the
therapeutic effect for up to 35 days after a single injection of
SPME-LA. Thus, the injectable SPME gel system represents a
promising platform for the sustained delivery of LA to achieve
long-term effects in vivo.References
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